Results 101 to 110 of about 41,377 (182)

QT interval prolongation and its related factors before and after receiving lopinavir-ritonavir in the COVID-19 era: a historical cohort study. [PDF]

Virus Res
Jangjou A, Izadpanah P, Moqhadas M, Faramarzi H, Fahimi MH, Ghazipoor H, Hamrah H, Kamyab H.   +7 more
europepmc   +1 more source

Physiologically Based Pharmacokinetic Modeling to Assess Antiretroviral-BTK Inhibitor Interactions and Provide Recommendations for Co-Administration Regimens. [PDF]

Pharmaceutics
Chen L, Wang X, Li L, Yang Y, Liu Y, Chen W.   +5 more
europepmc   +1 more source

A study on the stability of ritonavir form III processed in orbit and returned to Earth. [PDF]

NPJ Microgravity
Bauser HC, Smith PA, Parent SD, Chan LR, Bhavsar AS, Condon KH, McCalip A, Croom JM, Purcell DK, Bogdanowich-Knipp SJ, Smith DT, Cowans BA, Alajlouni R, Byrn SR, Radocea A.   +14 more
europepmc   +1 more source

Pharmacokinetics of Dexamethasone in Tuberculous Meningitis. [PDF]

Clin Infect Dis
Calderin JM, Resendiz-Galvan JE, Abdelgawad N, Davis A, Stek C, Wiesner L, Meintjes G, Wilkinson RJ, Denti P, Wasserman S.   +9 more
europepmc   +1 more source

Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients. [PDF]

N Engl J Med
Butler CC, Pinto AD, Harris V, Holmes J, Rahman NM, Cureton L, Hayward G, Richards DB, Lowe DM, Standing JF, Breuer J, Hood K, Png ME, Petrou S, Dorward J, Patel MG, Thomas NPB, Evans P, Hart ND, Jani BD, Hosseini B, Murthy S, McBrien K, Condon A, McDonald EG, Daley P, Greiver M, da Costa BR, Selby P, Jüni P, Lee TC, Shi H, Detry MA, Saunders CT, Fitzgerald M, Berry NS, Saville BR, Khoo SH, Nguyen-Van-Tam JS, Hobbs FDR, Yu LM, Little P, PANORAMIC Trial and CanTreatCOVID Trial Collaborative Groups.   +42 more
europepmc   +1 more source

Safety, Pharmacokinetics, and Dose Recommendations for Nirmatrelvir/Ritonavir in Individuals with Mild to Moderate COVID-19 and Severe Renal Impairment. [PDF]

Clin Pharmacol Ther
Gerhart J, Bramson CR, Goulding M, Shi H, Oladoyinbo O, Chan PLS, Chime S, Hammond J.   +7 more
europepmc   +1 more source

International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness. [PDF]

Clin Infect Dis
Kuriakose S, Tseng A, Boyd S, Gibbons S, Chiong J, Marra F, Boyle A, Senneker T, George J, Lund C, Belperio P, Crew P, Eschenauer G, Scarsi KK, Khoo SH, Pau A, Marzolini C, LiON-PK collaboration .   +17 more
europepmc   +1 more source

Profound Synergistic Bradycardia: Pharmacokinetic Consequences of Paxlovid-Mediated CYP3A4 and CYP2D6 Inhibition on Ranolazine, Diltiazem, and Metoprolol. [PDF]

Cureus
Bactawar SB, Gaibor C, Abdul-Waheed M.
europepmc   +1 more source

Nirmatrelvir/ritonavir reduced mortality in severe or critical COVID-19 patients: a multicenter retrospective cohort study. [PDF]

Front Med (Lausanne)
Zhao H, Meng W, Lv X, Si S, Wu S, Li J, Cai Z, Jin R, Yang L, Li C, Song L.   +10 more
europepmc   +1 more source

Economic Evaluation of Oral Nirmatrelvir-Ritonavir for COVID-19 in Higher Risk Outpatients.

JAMA Netw Open
Png ME, Harris V, Yu LM, Little P, Hobbs FDR, Butler CC, Petrou S, PANORAMIC Trial Collaborative Group.   +7 more
europepmc   +1 more source